Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

被引:186
作者
Fagan, Dedra H. [1 ]
Yee, Douglas [1 ,2 ]
机构
[1] Univ Minnesota, Dept Pharmacol, Mason Canc Ctr, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
关键词
Breast cancer; Estrogen receptor; Insulin-like growth factors;
D O I
10.1007/s10911-008-9098-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
After the discovery that depriving certain breast tumors of estrogen promoted tumor regression, therapeutic strategies aimed at depriving tumors of this hormone were developed. The tumorigenic properties of estrogen are regulated through the estrogen receptor-alpha (ER), making understanding the mechanisms that activate this receptor highly relevant. In addition to estrogen activating the ER, other growth factor pathways, such as the insulin-like growth factors (IGFs), can activate the ER. This review will examine the interaction between these two pathways. Estrogen can activate the growth stimulatory properties of the IGF pathway via ER's genomic and non-genomic functions. Further, blockade of ER function can inhibit IGF-mediated mitogenesis and blocking IGF action can inhibit estrogen stimulation of breast cancer cells. Collectively, these observations suggest that the two growth regulatory pathways are tightly linked and a more thorough understanding of the mechanism of this crosstalk could lead to improved therapeutic strategies in breast cancer.
引用
收藏
页码:423 / 429
页数:7
相关论文
共 78 条
[1]
An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis [J].
Alexia, C ;
Fallot, G ;
Lasfer, M ;
Schweizer-Groyer, G ;
Groyer, A .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) :1003-1015
[2]
Allen E, 1923, JAMA-J AM MED ASSOC, V81, P810
[3]
[Anonymous], CLIN CANC RES S
[4]
Baum M, 2002, LANCET, V359, P2131
[5]
GENE-REGULATION BY STEROID-HORMONES [J].
BEATO, M .
CELL, 1989, 56 (03) :335-344
[6]
Beatson G.T., 1896, LANCET, V148, P162, DOI DOI 10.1016/S0140-6736(01)72384-7
[7]
Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds [J].
Bonnette, SG ;
Hadsell, DL .
ENDOCRINOLOGY, 2001, 142 (11) :4937-4945
[8]
Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation [J].
Bunone, G ;
Briand, PA ;
Miksicek, RJ ;
Picard, D .
EMBO JOURNAL, 1996, 15 (09) :2174-2183
[9]
The IGF-I/IGF-I receptor pathway: Implications in the pathophysiology of thyroid cancer [J].
Ciampolillo, A ;
De Tullio, C ;
Giorgino, F .
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (24) :2881-2891
[10]
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871 [J].
Cohen, BD ;
Baker, DA ;
Soderstrom, C ;
Tkalcevic, G ;
Rossi, AM ;
Miller, PE ;
Tengowski, MW ;
Wang, F ;
Gualberto, A ;
Beebe, JS ;
Moyer, JD .
CLINICAL CANCER RESEARCH, 2005, 11 (05) :2063-2073